3M Drug Delivery Systems Forms Collaboration with Presspart Group for Dose Counter Technologies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

3M Drug Delivery Systems Forms Collaboration with Presspart Group for Dose Counter Technologies


3M Drug Delivery Systems Division has announced a collaborative agreement with specialist medical device and pharmaceutical component manufacturer, Presspart Group (a division of the German-based Heitkamp & Thumann Group). Under the terms of the agreement, Presspart is licensed to sell 3M’s Dose by Dose Counter and Dose Indicator, adding to its portfolio of capabilities with metered dose inhaler (MDI) actuators.

The agreement enables both organizations the opportunity to accelerate growth of dose counter technology in existing and future MDI development, with expanded access to a range of actuator configurations.

3M Drug Delivery Systems will continue to support its customers and offer the Dose by Dose Counter and Dose Indicator to future customers as part of its end-to-end inhalation technology expertise. Both technologies are compatible with most valves, and are customizable to meet partners’ requirements. They are easy for patients to use and retain a familiar actuator look and feel.

The 3M Dose Counter technology is available for third-party developments and has been approved by FDA in conjunction with an MDI product. It notifies patients of exactly how many doses of medication they have left in their MDI and helps prevent them from running out unexpectedly, thus protecting them from an unsafe situation. It also has the potential to minimize wastage of medication, which may have a positive effect on healthcare costs.  Its clear display is easy to understand for a wide range of users, young and old, giving an incremental indication of doses remaining in the MDI.

Source: 3M Drug Delivery Systems Division 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here